This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Kymab Limited
Kymab Limited, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on the development of innovative therapies for autoimmune diseases and cancer. Founded in 2010, Kymab has made significant strides in the biotechnology sector, particularly with its proprietary antibody platform, which enables the creation of unique monoclonal antibodies. The company’s flagship product, KY1005, is designed to modulate immune responses, showcasing Kymab's commitment to addressing unmet medical needs. With a strong presence in both the UK and the US, Kymab has established itself as a key player in the biopharmaceutical industry, recognised for its cutting-edge research and development capabilities. Notable achievements include successful clinical trials and strategic partnerships that enhance its market position and drive future growth.
DitchCarbon Score
How does Kymab Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kymab Limited's score of 23 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kymab Limited's reported carbon emissions
Kymab Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary and may inherit climate-related data from its parent organization, but no specific details are provided regarding this cascade. In terms of climate commitments, Kymab Limited has not outlined any reduction targets or initiatives, including those aligned with the Science Based Targets initiative (SBTi) or other industry standards. The lack of documented climate pledges suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. As the industry increasingly prioritises carbon neutrality and climate action, Kymab Limited's future commitments and potential emissions data will be crucial for assessing its environmental impact and alignment with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kymab Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
